title: Mometasone furoate ointment and cream 0.1 percent in treatment of psoriasis: comparison with ointment and cream formulations of fluocinolone acetonide 0.025 percent and triamcinolone acetonide 0.1 percent.
abstract: Mometasone furoate (Elocon) is a newly formulated and unique medium-potency synthetic 17-heterocyclic corticosteroid. The efficacy and safety of the ointment and cream formulations (0.1 percent) of the corticosteroid, administered once daily, were compared with those of the ointment and cream formulations of fluocinolone acetonide 0.025 percent administered three times daily and triamcinolone acetonide 0.1 percent administered twice daily in four multicenter clinical studies. They were conducted involving psoriasis patients with chronic and moderate to severe disease. Evaluation of change in disease sign scores indicated that mometasone ointment, applied once daily, was significantly more effective (P less than 0.01) than fluocinolone ointment, applied three times daily, and triamcinolone ointment, applied twice daily. The cream formulation of mometasone was significantly more effective (p less than 0.001) than fluocinolone cream, applied three times daily, and equivalent to triamcinolone cream, applied twice daily. The incidence of local adverse experiences following treatment with the ointment or cream formulations of mometasone was minimal. Mometasone ointment and cream provide a highly effective once-a-day treatment for moderate to severe psoriasis with minimal risk of side effects.
authors.affiliation: Schering Corporation, Keniworth, New Jersey 07033.
authors.forename: R S
authors.initials: RS
authors.lastname: Medansky
authors.forename: R
authors.initials: R
authors.lastname: Bressinck
authors.forename: G W
authors.initials: GW
authors.lastname: Cole
authors.forename: J H
authors.initials: JH
authors.lastname: Deeken
authors.forename: C N
authors.initials: CN
authors.lastname: Ellis
authors.forename: J D
authors.initials: JD
authors.lastname: Guin
authors.forename: J H
authors.initials: JH
authors.lastname: Herndon
authors.forename: A E
authors.initials: AE
authors.lastname: Lasser
authors.forename: E
authors.initials: E
authors.lastname: Leibsohn
authors.forename: M A
authors.initials: MA
authors.lastname: Menter
mesh_terms: D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005446:Fluocinolone Acetonide / Q000627:therapeutic use*; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D000068656:Mometasone Furoate; D015337:Multicenter Studies as Topic; D009824:Ointments; D011244:Pregnadienediols / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D011897:Random Allocation; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D009824:Ointments; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D005446:Fluocinolone Acetonide; D014222:Triamcinolone Acetonide